FDA approved EGFR inhibitors as the first line of treatment for advanced NSCLC patients positive for EGFR activating mutation [6], [7], but not for patients with wild-type EGFR, wherein in contrast an inferior outcome is observed in response to the treatment [8], [9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.